• SAR131675: A Selective VEGFR-3 Inhibitor for Fibrosis and Tu

  2026-08-06

  SAR131675 stands out as a highly selective, ATP-competitive VEGFR-3 inhibitor with robust anti-lymphangiogenic and anti-angiogenic properties. Its precise inhibition of VEGFR-3 makes it indispensable for dissecting lymphatic and vascular pathways in advanced fibrosis, tumor, and immunometabolic models.

• CAPE: Precision NF-κB Inhibition in Neurodegeneration Resear

  2026-08-06

  Explore how Caffeic Acid Phenethyl Ester (CAPE) enables translational researchers to dissect NF-κB-driven neuroinflammation and angiogenesis, with actionable protocol guidance and strategic insights that bridge mechanistic understanding to advanced model systems for neurodegenerative disease.

• LPS-Mediated Macrophage Protection via System Xc− and ABCC1

  2026-08-05

  The referenced study elucidates how lipopolysaccharide (LPS) protects macrophages from the cytotoxic effects of antitumor drugs by upregulating system Xc− and engaging ABCC1-mediated transport, independent of canonical TLR4 or caspase-11 signaling. These findings offer mechanistic insight into selective immune preservation during chemotherapy and highlight molecular targets for safer therapeutic strategies.

• Deciphering Native Protein Gel Electrophoresis: Beyond Proto

  2026-08-05

  Explore how the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit enables high-fidelity native protein gel electrophoresis while preserving protein structure and function. This article reveals advanced assay design principles and data-driven insights not covered in standard guides.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-08-04

  Explore the multifaceted role of 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine as a selective α2-adrenergic receptor agonist in immune rejection modulation and post-surgery osteosarcoma recurrence treatment research. This article delivers a unique mechanistic and workflow-driven perspective, surpassing prior reviews by highlighting advanced applications and practical assay considerations.

• Strategic CXCR4 Antagonism: Mavorixafor Hydrochloride in Tra

  2026-08-04

  This article provides an advanced, evidence-integrated perspective on leveraging Mavorixafor hydrochloride (AMD-070 hydrochloride) as a CXCR4 antagonist in translational workflows, with a particular focus on Waldenström’s Macroglobulinemia, CXCR4-driven immunological disorders, and anti-HIV research. We combine mechanistic insights, protocol strategies, and actionable guidance for researchers seeking to bridge assay performance with clinical relevance—positioning this discussion beyond conventional product summaries.

• Substrate Stiffness Regulates Dentinogenesis via LAMB1–FAK–M

  2026-08-03

  This study uncovers how substrate stiffness influences odontoblast-like cell differentiation and dentin matrix formation through a LAMB1–FAK–MEK1/2 signaling pathway. The findings advance our understanding of mechanotransduction in dental tissue engineering and highlight focal adhesion kinase as a key regulatory node.

• Standardized Whole-Blood Immune Response Assay with Metaboli

  2026-08-03

  This study establishes a protocol for analyzing the human immune response using whole-blood stimulation combined with targeted metabolic interventions. The approach enables precise dissection of how metabolic pathways, such as glycolysis and fatty acid oxidation, regulate cytokine production, with significant implications for immunometabolism and translational immunology.

• DiR (DiIC 18 (7)) for Long-Term Membrane Tracking in EV Stud

  2026-08-02

  DiR (DiIC 18 (7)) sets a benchmark for deep-red, low-toxicity membrane labeling, excelling in advanced extracellular vesicle (EV) tracking and neuronal tracing. Its robust in vivo stability and near-infrared sensitivity empower translational workflows in both live and fixed tissue imaging.

• Thymoquinone Mitigates Doxorubicin-Induced Cardiotoxicity vi

  2026-08-01

  This study provides the first direct evidence that thymoquinone, a bioactive compound from Nigella sativa, protects against doxorubicin-induced cardiotoxicity in mice by activating the Nrf2/HO-1 signaling pathway and reducing ferroptosis. These findings inform the design of future preclinical research into chemotherapeutic cardiac injury and antioxidant defense mechanisms.

• Recombinant Mouse IFN-γ: Advancing Antigen Presentation Assa

  2026-07-31

  Unlock robust immunomodulatory and antiviral workflows with APExBIO’s high-purity Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid). This guide details optimized protocols, troubleshooting, and the latest metabolic-immune mechanistic insights for restoring antigen presentation in challenging cancer models.

• MK-571 (L-660,711) for Inflammation & Drug Resistance Assays

  2026-07-31

  MK-571 (L-660,711) is a dual-action tool enabling precise dissection of leukotriene-driven inflammation and multidrug resistance in immune cell and pulmonary models. Its validated workflows and robust specificity make it a standout choice for researchers seeking clarity in complex mechanistic studies.

• Experimental Guidance for Cathepsin B inhibitor CA-074 (A192

  2026-07-30

  Cathepsin B inhibitor CA-074 offers researchers a nanomolar-selective tool for dissecting cathepsin B–mediated pathways in cancer metastasis, neurotoxicity, and immune modulation. The compound is best used in well-controlled biochemical and cellular assays where cathepsin B specificity and minimal off-target effects are critical. It is not designed for long-term solution storage or studies requiring broad-spectrum cysteine protease inhibition.

• Y-27632 ROCK Inhibitor: Precision Tools for Cytoskeletal Dyn

  2026-07-30

  Y-27632, a selective ROCK inhibitor, is transforming advanced cell models and cytoskeletal modulation workflows. This article delivers actionable guidance on experimental setup, troubleshooting, and optimization, bridging foundational research with emerging disease models.

• Q-VD-OPh: Pan-Caspase Inhibitor for Targeted Apoptosis Resea

  2026-07-29

  Q-VD-OPh is a potent, irreversible pan-caspase inhibitor that enables precise blockade of caspase-mediated apoptosis. Its high selectivity, cell and brain permeability, and robust activity across species make it a gold standard reagent for apoptosis research and neurodegenerative disease modeling.

455 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page